Resultados de procura - Suzanne Trudel

Limitar resultados
  1. 1
    Antibodies and bispecifics for multiple myeloma: effective effector therapy

    Antibodies and bispecifics for multiple myeloma: effective effector therapy por Christopher Cipkar, Christine Chen, Suzanne Trudel

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Actin assembly in electropermeabilized neutrophils: role of intracellular calcium.

    Actin assembly in electropermeabilized neutrophils: role of intracellular calcium. por Gregory P. Downey, C K Chan, Suzanne Trudel, Sergio Grinstein

    Publicado 1990
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma

    Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma por Hong Chang, A. Keith Stewart, Qi Xiao, Zhihua Li, Qi Long Yi, Suzanne Trudel

    Publicado 2005
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma

    Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma por Suzanne Trudel, Zhihua Li, Jennifer Rauw, Rodger E. Tiedemann, Xiao‐Yan Wen, A. Keith Stewart

    Publicado 2007
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma

    Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma por Suzanne Trudel, Scott Ely, Yildiz Farooqi, Maurizio Affer, Davide F. Robbiani, Marta Chesi, P. Leif Bergsagel

    Publicado 2004
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance

    Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance por Wilfrid Jaksic, Suzanne Trudel, Hong Chang, Young Trieu, Qi Xi, Joseph Mıkhael, Donna Reece, Christine Chen, A. Keith Stewart

    Publicado 2005
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

    CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma por Suzanne Trudel, Zhihua Li, Ellen Wei, Marion Wiesmann, Hong Chang, Christine Chen, Donna Reece, Carla Heise, A. Keith Stewart

    Publicado 2004
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma

    Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma por Donna Reece, Giovanni Piza Rodriguez, Christine Chen, Suzanne Trudel, Vishal Kukreti, Joseph Mıkhael, Mariela Pantoja, Wei Xu, A. Keith Stewart

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

    Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival por Víctor H. Jiménez‐Zepeda, Joseph Mıkhael, Andrew Winter, Norman Franke, Esther Masih‐Khan, Suzanne Trudel, Christine Chen, Vishal Kukreti, Donna Reece

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma

    Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma por James W. Clendening, Aleksandra A. Pandyra, Zhihua Li, Paul C. Boutros, Աննա Մարտիրոսյան, Richard Lehner, Igor Jurišica, Suzanne Trudel, Linda Z. Penn

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

    The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development por Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, María‐Victoria Mateos, Meletios Α. Dimopoulos, Sagar Lonial

    Publicado 2025
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  12. 12
    D(T)<scp>PACE</scp> as salvage therapy for aggressive or refractory multiple myeloma

    D(T)<scp>PACE</scp> as salvage therapy for aggressive or refractory multiple myeloma por Alina S. Gerrie, Joseph Mıkhael, Lu Cheng, Haiyan Jiang, Vishal Kukreti, Tony Panzarella, Donna Reece, Keith Stewart, Young Trieu, Suzanne Trudel, Christine I. Chen

    Publicado 2013
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma

    MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma por Esther Masih‐Khan, Suzanne Trudel, Carla Heise, Zhihua Li, Joshua Paterson, Vincent Nadeem, Ellen Wei, David Roodman, Jaime O. Claudio, P. Leif Bergsagel, A. Keith Stewart

    Publicado 2006
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop

    Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop por Aleksandra A. Pandyra, Peter Mullen, Manpreet Kalkat, Rosemary Yu, Janice T. Pong, Zhihua Li, Suzanne Trudel, Karl S. Lang, Mark D. Minden, Aaron D. Schimmer, Linda Z. Penn

    Publicado 2014
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

    A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma por Melissa Alsina, Suzanne Trudel, Richard R. Furman, Peter J. Rosen, Owen A. O’Connor, Raymond L. Comenzo, Alvin Wong, Lori Kunkel, Christopher J. Molineaux, André Goy

    Publicado 2012
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules

    Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules por Steven Fletcher, Brent D. G. Page, Xiaolei Zhang, Peibin Yue, Zhihua Li, Sumaiya Sharmeen, Jagdeep Singh, Wei Zhao, Aaron D. Schimmer, Suzanne Trudel, James Turkson, Patrick T. Gunning

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain

    Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain por Brent D. G. Page, Steven Fletcher, Peibin Yue, Zhihua Li, Xiaolei Zhang, Sumaiya Sharmeen, Alessandro Datti, Jeffrey L. Wrana, Suzanne Trudel, Aaron D. Schimmer, James Turkson, Patrick T. Gunning

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

    Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial por Suzanne Trudel, Arleigh McCurdy, Martha L Louzada, Stephen Parkin, Darrell White, Michael P. Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Donna Reece

    Publicado 2024
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

    Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study por Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves, Edward N. Libby, Paul G. Richardson, Axel Hoos, Ira Gupta, Véronique Bragulat, Zangdong He, Joanna Opalinska, Adam D. Cohen

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

    Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Synd... por Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer, Rayan Kaedbey, Paula Rodríguez‐Otero, Simon J. Harrison, Chihunt Wong, Grant R. Goodman, Rin Nakamura, Voleak Choeurng, James Fenimore Cooper, María‐Victoria Mateos

    Publicado 2022
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: